drugset / Trial / NCT02177500

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

NCT02177500

Phase 3 Completed 327 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and systolic blood pressure in patients who fail to respond adequately to telmisartan monotherapy.

Timeline

Start
2000-01
Primary completion
2000-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Telmisartan Other / unclassified 40 mg

Indications